# Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

> **NCT06037148** · PHASE1 · COMPLETED · sponsor: **Desentum Oy** · enrollment: 30 (actual)

## Conditions studied

- Birch Pollen Allergy

## Interventions

- **BIOLOGICAL:** DM-101PX
- **BIOLOGICAL:** Placebo to Match DM-101PX

## Key facts

- **NCT ID:** NCT06037148
- **Lead sponsor:** Desentum Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-07
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-03-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037148, "Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06037148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*